Overview

ADVATE Post Authorization Safety Surveillance

Status:
Completed

Trial end date:
2007-03-02

Target enrollment:

Participant gender:

Summary

The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.

Details

Lead Sponsor:

Baxalta now part of Shire
Baxalta US Inc.

Collaborator:

Baxter BioScience